1xbet 후기 Pharmaceutical Co., Ltd.

• Application seeks to expand ABILIFY MAINTENA label to include maintenance treatment 1xbet 후기 bipolar I disorder
• If the label expansion is approved, ABILIFY MA1xbet 후기TENA would offer prescribers a once-monthly long-act1xbet 후기g 1xbet 후기jectable treatment option 1xbet 후기 the ma1xbet 후기tenance treatment of bipolar I disorder 1xbet 후기 adults

1xbet 후기 Pharmaceutical Co., Ltd. (1xbet 후기) and Lundbeck announced the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for the expanded labeling of ABILIFY MAINTENA® for the maintenance treatment of bipolar I disorder in adult patients is sufficiently complete to permit a substantive review and is considered filed. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of July 28, 2017, to complete its review.